Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: A cost-effectiveness analysis

Arthritis Care and Research

Volumn 55, Issue 3, 2006, Pages 402-410

  Li, Linda C ^a,f   Maetzel, Andreas ^b,c   Davis, Aileen M ^c   Lineker, Sydney C ^d   Bombardier, Claire ^e   Coyte, Peter C ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d Arthritis Society   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Cost effectiveness analysis; Primary therapist model; Rehabilitation; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CANADA; CAREGIVER; COMORBIDITY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DRUG USE; EMPLOYMENT; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; OCCUPATIONAL THERAPIST; PHYSIOTHERAPIST; PHYSIOTHERAPY; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TECHNICAL AID; TRADITIONAL MEDICINE;

ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMIC; PATIENT CARE TEAM; PHYSICAL THERAPY (SPECIALTY); REFERRAL AND CONSULTATION; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 33745079699     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.21989     Document Type: Article

References (41)

1. Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH. Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 2002;47:672-85.
2. Li LC, Iversen MD. Outcomes of patients with rheumatoid arthritis receiving rehabilitation. Curr Opin Rheumatol 2005;17:172-6.
3. Li LC, Bombardier C. Utilization of physiotherapy and occupational therapy by Ontario rheumatologists in managing rheumatoid arthritis: a survey. Physiother Can 2003;55:23-30.
4. Lineker SC, Wood H, Badley EM, Stegne L, Wilkins A. Evaluation of the primary therapist model of service delivery as implemented by The Arthritis Society, consultation and rehabilitation service. Phase 1: therapist survey. Working Paper 98-5. Toronto, Ontario, Canada: Arthritis Community Research & Evaluation Unit; 1998.
5. Hurst K. Multi-skilled health carers: nature, purpose and implications. Health Manpow Manage 1997;23:197-211.
6. Stokes BA, Helewa A, Lineker SC. Total assessment of rheumatoid polyarthritis: a postgraduate training program for physical and occupational therapists: a 20 year success story. J Rheumatol 1997;24:1634-8.
7. Li LC, Davis AM, Lineker SC, Coyte PC, Bombardier C. Effectiveness of the primary therapist model for rheumatoid arthritis rehabilitation: a randomized controlled trial. Arthritis Rheum 2006;55:42-52.
8. Li LC, Coyte PC, Lineker SC, Wood H, Renahan M. Ambulatory care or home-based treatment? An economic evaluation of two physiotherapy delivery options for people with rheumatoid arthritis. Arthritis Care Res 2000;13:183-90.
9. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
10. Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM. A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 1998;25:231-7.
11. Helewa A, Smythe HA, Goldsmith CH. Can specially trained physiotherapists improve the care of patients with rheumatoid arthritis? A randomized health care trial. J Rheumatol 1994;21:70-9.
12. Helewa A, Goldsmith CH, Lee P, Bombardier C, Hanes B, Smythe HA, et al. Effects of occupational therapy home service on patients with rheumatoid arthritis. Lancet 1991;337:1453-6.
13. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, and the Community Hypertension and Arthritis Project Study Team. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15. Schedule of Benefits. Physician services under the Health Insurance Act. Toronto, Ontario, Canada: Ontario Ministry of Health; 1998.
16. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655-61.
17. Management Information Systems Guidelines: Hospital Medical Records Institute. Ottawa, Ontario, Canada: Canadian Institute of Health Information; 1992.
18. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
19. Alberta Health and Wellness. Health costing in Alberta: 1999 annual report. Edmonton, Alberta, Canada: Alberta Health and Wellness; 1999.
20. Pharmaceutical catalogue. Toronto, Ontario, Canada: Kohl & Frisch Limited; 1999.
21. Ambulation aids product manual. Wheelchair, positioning and ambulation aids manual. Toronto, Ontario, Canada: Ontario Ministry of Health; 2000.
22. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
23. Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial: comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997;35:1109-18.
24. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
25. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H, and the Economic and Health Outcomes Research Group. Validity of Euroqol, a generic health status instrument, in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:655-62.
26. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
27. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15:209-31.
28. Johnson JA, Coons SJ, Ergo A, Szava-Kovats G. Valuation of EuroQoL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998;13:421-33.
29. Nord E. EuroQol: health-related quality of life measurement: valuations of health states by the general public in Norway. Health Policy 1991;18:25-36.
30. Brooks RG, Jendteg S, Lindgren B, Persson U, Bjork S. EuroQol: health-related quality of life measurement: results of the Swedish questionnaire exercise. Health Policy 1991;18:37-48.
31. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
32. Raboud JM, Singer J, Thorne A, Schechter MT, Shafran SD. Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death. Qual Life Res 1998;7:487-94.
33. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141-64.
34. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18 Suppl:S68-80.
35. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
36. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
37. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993;148:927-9.
38. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96.
39. Kvien TK, Uhlig T, Kristiansen IS. Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible. Drugs 2001;61:1711-20.
40. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
41. Coyte PC, Asche C, Croxford R, Chan B. The economic cost of arthritis and rheumatism in Canada. In: Badley EM, Williams JI, editors. Patterns of health care in Ontario: arthritis & related conditions. Toronto, Ontario, Canada: Institute for Clinical Evaluative Sciences; 1998. p. 27-34.